Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1

Immunology Letters

Volumn 104, Issue 1-2, 2006, Pages 146-155

  Zsebik, Barbara ^a   Citri, Ami ^b   Isola, Jorma ^c   Yarden, Yosef ^b   Szöllosi, János ^a   Vereb, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

17 AAG; Breast tumor immunotherapy; ErbB2; Trastuzumab

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN; TRASTUZUMAB;

APOPTOSIS; BREAST CANCER; BREAST TUMOR; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIMERIZATION; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STIMULUS; TUMOR CELL; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DIMERIZATION; DRUG RESISTANCE, NEOPLASM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RIFABUTIN;

EID: 33644694046     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2005.11.018     Document Type: Conference Paper

References (49)

1. L.N. Klapper, S. Glathe, N. Vaisman, N.E. Hynes, G.C. Andrews, and M. Sela The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proc Natl Acad Sci USA 96 1999 4995 5000
2. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
3. D. Karunagaran, E. Tzahar, N. Liu, D. Wen, and Y. Yarden Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases J Biol Chem 270 1995 9982 9990
4. P. Nagy, A. Jenei, S. Damjanovich, T.M. Jovin, and J. Szöllosi Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy Pathol Oncol Res 5 1999 255 271
5. G. Vereb, P. Nagy, J.W. Park, and J. Szöllosi Signaling revealed by mapping molecular interactions: implications for ErbB-targeted cancer immunotherapies Clin Appl Immunol Rev 2 2002 169 186
6. E. Tzahar, H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, and S. Lavi A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol Cell Biol 16 1996 5276 5287
7. A. Citri, K.B. Skaria, and Y. Yarden The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Exp Cell Res 284 2003 54 65
8. Z. Wang, L. Zhang, T.K. Yeung, and X. Chen Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation Mol Biol Cell 10 1999 1621 1636
9. D.S. Lidke, P. Nagy, R. Heintzmann, D.J. Arndt-Jovin, J.N. Post, and H. Grecco Quantum dot ligands provide new insights into ErbB/HER receptor-mediated signal transduction Nat Biotechnol 22 2004 198 203
10. A.E. Lenferink, R. Pinkas-Kramarski, M.L. van de Poll, M.J. van Vugt, L.N. Klapper, and E. Tzahar Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers Embo J 17 1998 3385 3397
11. R. Worthylake, L.K. Opresko, and H.S. Wiley ErbB-2 amplification inhibits downregulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors J Biol Chem 274 1999 8865 8874
12. P.P. Di Fiore, J.H. Pierce, M.H. Kraus, O. Segatto, C.R. King, and S.A. Aaronson ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells Science 237 1987 178 182
13. F. Lonardo, E. Di Marco, C.R. King, J.H. Pierce, O. Segatto, and S.A. Aaronson The normal ErbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand New Biol 2 1990 992 1003
14. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
15. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, and L. Dantis Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
16. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
17. D.B. Agus, R.W. Akita, W.D. Fox, G.D. Lewis, B. Higgins, and P.I. Pisacane Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 2002 127 137
18. J.G. Jackson, P. St Clair, M.X. Sliwkowski, and M.G. Brattain Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects Cancer Res 64 2004 2601 2609
19. W.J. Slichenmyer, W.L. Elliott, and D.W. Fry CI-1033, a pan-ErbB tyrosine kinase inhibitor Semin Oncol 28 2001 80 85
20. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726
21. H. Burris III, D. Yardley, S. Jones, G. Houston, C. Broome, and D. Thompson Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer J Clin Oncol 22 2004 1621 1629
22. A.B. Motoyama, N.E. Hynes, and H.A. Lane The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res 62 2002 3151 3158
23. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 2001 1852 1857
24. P. Nagy, E. Friedländer, M. Tanner, A.I. Kapanen, K.L. Carraway, and J. Isola Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res 65 2005 473 482
25. E. Friedländer, D.J. Arndt-Jovin, P. Nagy, T.M. Jovin, J. Szöllosi, and G. Vereb Signal transduction of ErbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy Cytometry A 67 2005 161 171
26. P. Nagy, L. Bene, M. Balázs, W.C. Hyun, S.J. Lockett, and N.Y. Chiang EGF-induced redistribution of ErbB2 on breast tumor cells: flow and image cytometric energy transfer measurements Cytometry 32 1998 120 131
27. H.S. Cho, K. Mason, K.X. Ramyar, A.M. Stanley, S.B. Gabelli, and D.W. Denney Jr. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 2003 756 760
28. J.C. Sarup, R.M. Johnson, K.L. King, B.M. Fendly, M.T. Lipari, and M.A. Napier Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth Growth Regul 1 1991 72 82
29. R.M. Neve, U.B. Nielsen, D.B. Kirpotin, M.A. Poul, J.D. Marks, and C.C. Benz Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function Biochem Biophys Res Commun 280 2001 274 279
30. P. Nagy, G. Vereb, Z. Sebestyén, G. Horváth, S.J. Lockett, and S. Damjanovich Lipid rafts and the local density or ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2 J Cell Sci 115 2002 4251 4262
31. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 26 1999 60 70
32. W.B. Pratt, and D.O. Toft Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery Exp Biol Med (Maywood) 228 2003 111 133
33. W. Xu, E. Mimnaugh, M.F. Rosser, C. Nicchitta, M. Marcu, and Y. Yarden Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 J Biol Chem 276 2001 3702 3708
34. W. Xu, X. Yuan, Z. Xiang, E. Mimnaugh, M. Marcu, and L. Neckers Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex Nat Struct Mol Biol 12 2005 120 126
35. A. Citri, J. Gan, Y. Mosesson, G. Vereb, J. Szöllosi, and Y. Yarden Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation EMBO Rep 5 2004 1165 1170
36. Y. Uehara, M. Hori, T. Takeuchi, and H. Umezawa Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase Jpn J Cancer Res 76 1985 672 675
37. L. Neckers, T.W. Schulte, and E. Mimnaugh Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity Invest New Drug 17 1999 361 373
38. J.G. Supko, R.L. Hickman, M.R. Grever, and L. Malspeis Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent Cancer Chemother Pharmacol 36 1995 305 315
39. T.W. Schulte, and L.M. Neckers The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin Cancer Chemother Pharmacol 42 1998 273 279
40. L.R. Kelland, S.Y. Sharp, P.M. Rogers, T.G. Myers, and P. Workman DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90 J Natl Cancer Inst 91 1999 1940 1949
41. P. Workman Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone Cancer Lett 206 2004 149 157
42. U. Banerji, A. O'Donnell, M. Scurr, S. Pacey, S. Stapleton, and Y. Asad Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 23 2005 4152 4161
43. O. Tikhomirov, and G. Carpenter Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation J Biol Chem 275 2000 26625 26631
44. D.B. Solit, F.F. Zheng, M. Drobnjak, P.N. Munster, B. Higgins, and D. Verbel 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin Cancer Res 8 2002 986 993
45. V. Smith, S. Hobbs, W. Court, S. Eccles, P. Workman, and L.R. Kelland ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin Anticancer Res 22 2002 1993 1999
46. M. Tanner, A.I. Kapanen, T. Junttila, O. Raheem, S. Grenman, and J. Elo Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer Mol Cancer Ther 3 2004 1585 1592
47. G. Vereb, J. Matkó, and J. Szöllosi Cytometry of fluorescence resonance energy transfer Meth Cell Biol 75 2004 105 152
48. C.D. Austin, A.M. De Maziere, P.I. Pisacane, S.M. van Dijk, C. Eigenbrot, and M.X. Sliwkowski Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol Biol Cell 15 2004 5268 5282
49. R. Mandler, H. Kobayashi, E.R. Hinson, M.W. Brechbiel, and T.A. Waldmann Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity Cancer Res 64 2004 1460 1467